Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANCRIT-1
2013-004516-21Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2014
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing 90Y-clivatuzumab tetraxetan + low-dose gemcitabine with Placebo + low-dose gemcitabine (2 arms). Primary endpoint: Overall survival. Started Jul 2014; status: completed.
02
Drugs
clivatuzumab tetraxetangemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2013-004516-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004516-21.